Radiopharmaceuticals heat anti-tumor immunity

Sun, Qi; Li, Jiyuan; Ding, Zexuan; Liu, Zhibo

doi:10.7150/thno.79806

Cited by 10 publications

(3 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the field of research on antitumor drugs, there has been a growing interest in the efficacy of various compounds, including PTX [ 133 ], cephalexin (CPT) [ 133 ], irinotecan hydrochloride (CPT-11) [ 134 ], and topotecan hydrochloride (TPT) [ 135 ]. These drugs have gathered attention due to their potential therapeutic benefits, in addition to DOX.…”

Section: Research On Polysaccharide-aunps As Drug Delivery Carriersmentioning

confidence: 99%

Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery

Song,

Aipire,

Dilxat

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Clinical drug administration aims to deliver drugs efficiently and safely to target tissues, organs, and cells, with the objective of enabling their therapeutic effects. Currently, the main approach to enhance a drug’s effectiveness is ensuring its efficient delivery to the intended site. Due to the fact that there are still various drawbacks of traditional drug delivery methods, such as high toxicity and side effects, insufficient drug specificity, poor targeting, and poor pharmacokinetic performance, nanocarriers have emerged as a promising alternative. Nanocarriers possess significant advantages in drug delivery due to their size tunability and surface modifiability. Moreover, nano-drug delivery systems have demonstrated strong potential in terms of prolonging drug circulation time, improving bioavailability, increasing drug retention at the tumor site, decreasing drug resistance, as well as reducing the undesirable side effects of anticancer drugs. Numerous studies have focused on utilizing polysaccharides as nanodelivery carriers, developing delivery systems based on polysaccharides, or exploiting polysaccharides as tumor-targeting ligands to enhance the precision of nanoparticle delivery. These types of investigations have become commonplace in the academic literature. This review aims to elucidate the preparation methods and principles of polysaccharide gold nanocarriers. It also provides an overview of the factors that affect the loading of polysaccharide gold nanocarriers with different kinds of drugs. Additionally, it outlines the strategies employed by polysaccharide gold nanocarriers to improve the delivery efficiency of various drugs. The objective is to provide a reference for further development of research on polysaccharide gold nanodelivery systems.

show abstract

Section: Research On Polysaccharide-aunps As Drug Delivery Carriersmentioning

confidence: 99%

Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery

Song,

Aipire,

Dilxat

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Therefore, there is great potential for labeling antibodies or aptamers to MUC1 with radionuclides, which could enhance the therapeutic effect of drugs for cancer treatment [183]. Compared to traditional treatment methods, radiopharmaceutical therapy (RPT) is the least toxic and most targeted form of effective cancer treatment [184,185]. Although RPT has been shown to be an effective cancer treatment and has been clinically studied for over 40 years, it has not become part of the cancer treatment armamentarium like other therapies [184].…”

Section: Radiopharmaceuticalsmentioning

confidence: 99%

Mucin Glycans: A Target for Cancer Therapy

Sun,

Zhang,

et al. 2023

Molecules

View full text Add to dashboard Cite

Mucin glycans are an important component of the mucus barrier and a vital defence against physical and chemical damage as well as pathogens. There are 20 mucins in the human body, which can be classified into secreted mucins and transmembrane mucins according to their distributions. The major difference between them is that secreted mucins do not have transmembrane structural domains, and the expression of each mucin is organ and cell-specific. Under physiological conditions, mucin glycans are involved in the composition of the mucus barrier and thus protect the body from infection and injury. However, abnormal expression of mucin glycans can lead to the occurrence of diseases, especially cancer, through various mechanisms. Therefore, targeting mucin glycans for the diagnosis and treatment of cancer has always been a promising research direction. Here, we first summarize the main types of glycosylation (O-GalNAc glycosylation and N-glycosylation) on mucins and the mechanisms by which abnormal mucin glycans occur. Next, how abnormal mucin glycans contribute to cancer development is described. Finally, we summarize MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example. In this section, we specifically elaborate on the recent new cancer therapy CAR-M, which may bring new hope to cancer patients.

show abstract

“…Radiotherapy is a powerful therapeutic modality of cancer which can kill tumor cells through direct DNA damage and indirect reactive oxygen species (ROS) damage without tissue penetration limitation [ 6 , 26 , 27 , 28 ]. Recently, it has been reported that RT can induce ICD with TAA and DAMP release, thereby triggering DC maturation and eliciting antitumor immune responses [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ]. It is widely reported that the coordinated high-order metal elements in nanocrystals can induce tumor ICD via radiotherapy.…”

Section: Radiotherapymentioning

confidence: 99%

Nanotechnology-Assisted Immunogenic Cell Death for Effective Cancer Immunotherapy

Guo,

Ma,

Zhang

et al. 2023

Vaccines

View full text Add to dashboard Cite

Tumor vaccines have been used to treat cancer. How to efficiently induce tumor-associated antigens (TAAs) secretion with host immune system activation is a key issue in achieving high antitumor immunity. Immunogenic cell death (ICD) is a process in which tumor cells upon an external stimulus change from non-immunogenic to immunogenic, leading to enhanced antitumor immune responses. The immune properties of ICD are damage-associated molecular patterns and TAA secretion, which can further promote dendritic cell maturation and antigen presentation to T cells for adaptive immune response provocation. In this review, we mainly summarize the latest studies focusing on nanotechnology-mediated ICD for effective cancer immunotherapy as well as point out the challenges.

show abstract

Radiopharmaceuticals heat anti-tumor immunity

Cited by 10 publications

References 145 publications

Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery

Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery

Mucin Glycans: A Target for Cancer Therapy

Nanotechnology-Assisted Immunogenic Cell Death for Effective Cancer Immunotherapy

Contact Info

Product

Resources

About